CHARLES J PARKER M.D.
Prescription History 1790735686
Internal Medicine - Hematology in Salt Lake City, UT


Quality Rating: 92.06 out of 100 score

NPI Status: Active since May 11, 2006

Contact Information

1950 CIRCLE OF HOPE DR
SALT LAKE CITY, UT
ZIP 84112
Phone: (801) 581-2121

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CHARLES J PARKER M.D., an active Hematology specialist practicing in Salt Lake City, UT. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 26 documented patient claims. Among these therapy options, the most frequently utilized medication is Promacta, which accounts for 15 claims alone.

Medication Index

No matching medications currently found on file.

Deferasirox

Generic Formulation: DeferasiroxSpecialty: Hematology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
UT State Average Benchmarks
Peer Average Claims11.0
Peer Average 30-Day Fills11.5
Peer Average Days Supply345
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $75,923.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,902.10

State Avg Cost Per Claim

$2,297.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.

Therapeutic Applications

This medication is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia). It works by binding to iron, allowing the body to pass extra iron out in the stool. Deferasirox belongs to a class of drugs known as iron-chelating agents. Frequent blood transfusions are often needed in certain types of blood diseases (such as sickle cell disease, anemia). Blood transfusions have very helpful benefits, but they can cause the body to hold on to too much iron. The extra iron can build up in the body and cause problems such as heart failure, liver disease, and diabetes. Getting rid of extra iron can decrease the risk of these diseases.

Promacta

Generic Formulation: Eltrombopag OlamineSpecialty: Hematology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 446
UT State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.0
Peer Average Days Supply414
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $102,906.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,860.45

State Avg Cost Per Claim

$12,818.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CHARLES J PARKER M.D. provides transparency into local medical care patterns within Salt Lake City, UT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.